Skip to main content
SpringerLink
Log in

Carcinoid Heart Disease: a Comprehensive Review

  • Valvular Heart Disease (TL Kiefer, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Carcinoid heart disease is a rare disorder that is associated with significant morbidity and mortality. In this review of the literature, we will present current concepts in diagnosis and management of carcinoid heart disease.

Recent Findings

Recent expert consensus guidelines highlight the role of echocardiography and screening with NT-proBNP for the evaluation of carcinoid heart disease. Advances in medical therapy along with better surgical outcomes highlight the experience and expertise that has been gained in the treatment of carcinoid heart disease.

Summary

Carcinoid heart disease occurs in patients with neuroendocrine tumors who have carcinoid syndrome. Serotonin appears to play a central role in the development of carcinoid heart disease. Cardiac biomarkers and multimodality imaging can be used to aid in screening and diagnosis. The mainstay of treatment of carcinoid heart disease is surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87(4):1188–96.

    Article  CAS  Google Scholar 

  2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77(2):264–9.

    Article  CAS  Google Scholar 

  4. Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci. 1994;733:464–70.

    Article  CAS  Google Scholar 

  5. Castillo JG, Silvay G, Solis J. Current concepts in diagnosis and perioperative management of carcinoid heart disease. Semin Cardiothorac Vasc Anesth. 2013;17(3):212–23. https://doi.org/10.1177/1089253212465475.

    Article  PubMed  Google Scholar 

  6. Etienne N, Schaerlinger B, Jaffre F, Maroteaux L. The 5-HT2B receptor: a main cardio-pulmonary target of serotonin. J Soc Biol. 2004;198(1):22–9.

    Article  CAS  Google Scholar 

  7. Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease--it was meant 2B. Pharmacol Ther. 2011;132(2):146–57. https://doi.org/10.1016/j.pharmthera.2011.03.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006;113(1):81–9. https://doi.org/10.1161/circulationaha.105.554667.

    Article  CAS  PubMed  Google Scholar 

  9. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813–29.

    Article  CAS  Google Scholar 

  10. Johnston SD, Johnston PW, O’Rourke D. Carcinoid constrictive pericarditis. Heart. 1999;82(5):641–3. https://doi.org/10.1136/hrt.82.5.641.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Marupakula V, Vinales KL, Najib MQ, Lanza LA, Lee HR, Chaliki HP. Occurrence of left-sided heart valve involvement before right-sided heart valve involvement in carcinoid heart disease. Eur J Echocardiogr. 2011;12(3):E18. https://doi.org/10.1093/ejechocard/jeq171.

    Article  PubMed  Google Scholar 

  12. Pandya UH, Pellikka PA, Enriquez-Sarano M, Edwards WD, Schaff HV, Connolly HM. Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients. J Am Coll Cardiol. 2002;40(7):1328–32.

    Article  Google Scholar 

  13. Tomaszewski A, Matuszek B, Zapolski T, Czekajska-Chehab E, Matuszek M, Rudzki S. Carcinoid heart disease as a first manifestation of midgut carcinoid tumor in a young woman. 2009.

  14. Blick DR, Zoghbi WA, Lawrie GM, Verani MS. Carcinoid heart disease presenting as right-to-left shunt and congestive heart failure: successful surgical treatment. Am Heart J. 1988;115(1 Pt 1):201–3.

    Article  CAS  Google Scholar 

  15. Biorck G, Axen O, Thorson A. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J. 1952;44(1):143–8.

    Article  CAS  Google Scholar 

  16. Eapen DJ, Clements S Jr, Block P, Sperling L. Metastatic carcinoid disease inducing coronary vasospasm. Tex Heart Inst J. 2012;39(1):76–8.

    PubMed  PubMed Central  Google Scholar 

  17. Petersen KG, Seemann WR, Plagwitz R, Kerp L. Evidence for coronary spasm during flushing in the carcinoid syndrome. Clin Cardiol. 1984;7(8):445–8. https://doi.org/10.1002/clc.4960070805.

    Article  CAS  PubMed  Google Scholar 

  18. Langer C, Piper C, Vogt J, Heintze J, Butz T, Lindner O, et al. Atrial fibrillation in carcinoid heart disease: the role of serotonin. A review of the literature. Clin Res Cardiol. 2007;96(2):114–8. https://doi.org/10.1007/s00392-006-0463-y.

    Article  CAS  PubMed  Google Scholar 

  19. Mehta AC, Rafanan AL, Bulkley R, Walsh M, DeBoer GE. Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. Chest. 1999;115(2):598–600. https://doi.org/10.1378/chest.115.2.598.

    Article  CAS  PubMed  Google Scholar 

  20. Rupp AB, Ahmadjee A, Morshedzadeh JH, Ranjan R. Carcinoid syndrome-induced ventricular tachycardia. Case Rep Cardiol. 2016;2016:9142598–3. https://doi.org/10.1155/2016/9142598.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Topol EJ, Fortuin NJ. Coronary artery spasm and cardiac arrest in carcinoid heart disease. Am J Med. 1984;77(5):950–2.

    Article  CAS  Google Scholar 

  22. Bourgault C, Bergeron S, Bogaty P, Poirier P. A most unusual acute coronary syndrome. Can J Cardiol. 2006;22(5):429–32. https://doi.org/10.1016/s0828-282x(06)70930-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Meurice J, Boule S, Deswarte G, Brigadeau F, Modine T. Solitary atrial myocardial metastasis revealing ileal neuroendocrine carcinoma. Cardiovasc Pathol. 2012;21(4):355–7. https://doi.org/10.1016/j.carpath.2011.10.003.

    Article  PubMed  Google Scholar 

  24. Sareyyupoglu B, Connolly HM, Schaff HV. Surgical excision of right ventricular carcinoid tumor in a symptomatic patient without carcinoid valve disease. J Thorac Cardiovasc Surg. 2010;140(2):e23–5. https://doi.org/10.1016/j.jtcvs.2009.07.072.

    Article  PubMed  Google Scholar 

  25. Rich LL, Lisa CP, Nasser WK. Carcinoid pericarditis. Am J Med. 1973;54(4):522–7.

    Article  CAS  Google Scholar 

  26. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One. 2013;8(9):e73679. https://doi.org/10.1371/journal.pone.0073679.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20. https://doi.org/10.1093/annonc/mdv041.

    Article  CAS  PubMed  Google Scholar 

  28. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102(7):938–42. https://doi.org/10.1016/j.amjcard.2008.05.047.

    Article  CAS  PubMed  Google Scholar 

  29. •• Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288–304. https://doi.org/10.1016/j.jacc.2016.12.030 Expert consensus statement of the diagnosis and management of carcinoid heart disease.

    Article  PubMed  Google Scholar 

  30. Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010;3(1):103–11. https://doi.org/10.1161/circimaging.109.886846.

    Article  PubMed  Google Scholar 

  31. Bhattacharyya S, Burke M, Caplin ME, Davar J. Utility of 3D transoesophageal echocardiography for the assessment of tricuspid and pulmonary valves in carcinoid heart disease. Eur J Echocardiogr. 2011;12(1):E4. https://doi.org/10.1093/ejechocard/jeq099.

    Article  PubMed  Google Scholar 

  32. Fazlinezhad A, Moravvej Z, Azari A, Bigdelu L. Carcinoid heart disease and the utility of 3D trans-thoracic and trans-esophageal echocardiography: two clinical cases. J Saudi Heart Assoc. 2014;26(1):51–5. https://doi.org/10.1016/j.jsha.2013.08.004.

    Article  PubMed  Google Scholar 

  33. Moerman VM, Dewilde D, Hermans K. Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance. Acta Cardiol. 2012;67(2):245–8. https://doi.org/10.2143/ac.67.2.2154218.

    Article  PubMed  Google Scholar 

  34. Agha AM, Lopez-Mattei J, Donisan T, Balanescu D, Iliescu CA, Banchs J, et al. Multimodality imaging in carcinoid heart disease. Open Heart. 2019;6(1):e001060. https://doi.org/10.1136/openhrt-2019-001060.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Rajiah P, Kanne JP, Kalahasti V, Schoenhagen P. Computed tomography of cardiac and pericardiac masses. J Cardiovasc Comput Tomogr. 2011;5(1):16–29. https://doi.org/10.1016/j.jcct.2010.08.009.

    Article  PubMed  Google Scholar 

  36. Khalique OK, Cavalcante JL, Shah D, Guta AC, Zhan Y, Piazza N, et al. Multimodality imaging of the tricuspid valve and right heart anatomy. J Am Coll Cardiol Img. 2019;12(3):516–31. https://doi.org/10.1016/j.jcmg.2019.01.006.

    Article  Google Scholar 

  37. Dobson R, Cuthbertson DJ, Jones J, Valle JW, Keevil B, Chadwick C, et al. Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease. Neuroendocrinology. 2014;99(2):85–93.

    Article  CAS  Google Scholar 

  38. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, et al. Carcinoid heart disease. Circulation. 1995;92(4):790–5. https://doi.org/10.1161/01.CIR.92.4.790.

    Article  CAS  Google Scholar 

  39. Denney WD, Kemp WE Jr, Anthony LB, Oates JA, Byrd BF 3rd. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol. 1998;32(4):1017–22.

    Article  CAS  Google Scholar 

  40. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. The New England journal of medicine. 2003;348(11):1005–15.

    Article  Google Scholar 

  41. Mansencal N, Mitry E, Bachet JB, Rougier P, Dubourg O. Echocardiographic follow-up of treated patients with carcinoid syndrome. The American journal of cardiology. 2010;105(11):1588–91.

    Article  Google Scholar 

  42. Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol. 1989;63(5):347–52.

    Article  CAS  Google Scholar 

  43. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA. Carcinoid heart disease. Prog Cardiovasc Dis. 2007;49(6):439–51. https://doi.org/10.1016/j.pcad.2006.12.002.

    Article  PubMed  Google Scholar 

  44. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63. https://doi.org/10.1200/jco.2009.22.8510.

    Article  CAS  PubMed  Google Scholar 

  45. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33. https://doi.org/10.1056/NEJMoa1316158.

    Article  CAS  PubMed  Google Scholar 

  46. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (London, England). 2016;387(10022):968–77. https://doi.org/10.1016/s0140-6736(15)00817-x.

    Article  CAS  Google Scholar 

  47. Faiss S, Pape U-F, Böhmig M, Dörffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21(14):2689–96. https://doi.org/10.1200/JCO.2003.12.142.

    Article  CAS  PubMed  Google Scholar 

  48. Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652–9. https://doi.org/10.1200/jco.2009.22.8585.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Pavel M, Horsch D, Caplin M, Ramage J, Seufferlein T, Valle J, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–9. https://doi.org/10.1210/jc.2014-2247.

    Article  CAS  PubMed  Google Scholar 

  50. Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25(2):410–6.

    Article  CAS  Google Scholar 

  51. Warner RRP, Castillo JG. Carcinoid heart disease: the challenge of the unknown known∗. J Am Coll Cardiol. 2015;66(20):2197–200. https://doi.org/10.1016/j.jacc.2015.05.086.

    Article  PubMed  Google Scholar 

  52. Connolly HM, Schaff HV, Mullany CJ, Abel MD, Pellikka PA. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation. 2002;106(12 Suppl 1):I51–i6.

    PubMed  Google Scholar 

  53. Castillo JG, Filsoufi F, Rahmanian PB, Zacks JS, Warner RR, Adams DH. Early bioprosthetic valve deterioration after carcinoid plaque deposition. Ann Thorac Surg. 2009;87(1):321. https://doi.org/10.1016/j.athoracsur.2008.04.061.

    Article  PubMed  Google Scholar 

  54. Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart. 2017;103(19):1488–95. https://doi.org/10.1136/heartjnl-2017-311261.

    Article  CAS  PubMed  Google Scholar 

  55. Westberg G, Wangberg B, Ahlman H, Bergh CH, Beckman-Suurkula M, Caidahl K. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg. 2001;88(6):865–72. https://doi.org/10.1046/j.0007-1323.2001.01798.x.

    Article  CAS  PubMed  Google Scholar 

  56. Moller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112(21):3320–7. https://doi.org/10.1161/circulationaha.105.553750.

    Article  PubMed  Google Scholar 

  57. • Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol. 2015;66(20):2189–96. https://doi.org/10.1016/j.jacc.2015.09.014 Surgical survival rates over time in patients who have had valve replacements for carcinoid heart disease. Surivival rates seemed to be tied to surgical center experience and era when the surgery was performed.

    Article  PubMed  Google Scholar 

  58. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BG. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. 2004;90(11):2073–9. https://doi.org/10.1038/sj.bjc.6601816.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32. https://doi.org/10.1136/gutjnl-2011-300831.

    Article  CAS  PubMed  Google Scholar 

  60. Robiolio PA, Rigolin VH, Harrison JK, Lowe JE, Moore JO, Bashore TM, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. 1995;75(7):485–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Saamir A. Hassan, Nicolas L. Palaskas, Ali M. Agha, Cezar Iliescu, Juan Lopez-Mattei & Syed Wamique Yusuf

  2. Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Christopher Chen & Henry Zheng

Authors
  1. Saamir A. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas L. Palaskas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali M. Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cezar Iliescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Lopez-Mattei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christopher Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Henry Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Syed Wamique Yusuf
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Conflict of Interest

Saamir A. Hassan, Nicolas L. Palaskas, Ali M. Agha, Cezar Iliescu, Juan Lopez-Mattei, Christopher Chen, Henry Zheng, and Syed Wamique Yusuf declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Valvular Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, S.A., Palaskas, N.L., Agha, A.M. et al. Carcinoid Heart Disease: a Comprehensive Review. Curr Cardiol Rep 21, 140 (2019). https://doi.org/10.1007/s11886-019-1207-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-019-1207-8

Keywords

Search

Navigation